16-Dehydro-pregnenolone/Atorvastatin

双烯醇酮乙酸酯/阿托伐他汀

Report date: 2022/01/14 13:23:58

Base Information

Drug Name16-Dehydro-pregnenolone/Atorvastatin
Drug Alias Name双烯醇酮乙酸酯-阿托伐他汀16-Dehydro-pregnenolone-Atorvastatin mixt双烯醇酮乙酸酯+阿托伐他汀16-Dehydro-pregnenolone and AtorvastatinAtorvastatin/16-Dehydro-pregnenolone +[11
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsDyslipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCadila Pharmaceuticals LtdCdri
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDyslipidemias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A